DA
REGN icon

Dillon & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Dillon & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.39M Buy
4,391
+18
+0.4% +$13.8K 0.47% 39
2025
Q4 		$3.38M Sell
4,373
-524
-11% -$356K 0.44% 38
2025
Q3 		$2.75M Sell
4,897
-8,447
-63% -$4.78M 0.35% 41
2025
Q2 		$7.01M Sell
13,344
-392
-3% -$219K 0.95% 29
2025
Q1 		$8.71M Sell
13,736
-163
-1% -$112K 1.29% 24
2024
Q4 		$9.9M Buy
13,899
+374
+3% +$314K 1.37% 24
2024
Q3 		$14.2M Buy
13,525
+878
+7% +$977K 2% 15
2024
Q2 		$13.3M Buy
12,647
+279
+2% +$270K 1.93% 14
2024
Q1 		$11.9M Buy
12,368
+573
+5% +$545K 1.87% 17
2023
Q4 		$10.4M Sell
11,795
-346
-3% -$285K 1.88% 17
2023
Q3 		$9.99M Buy
12,141
+378
+3% +$297K 1.92% 16
2023
Q2 		$8.46M Buy
11,763
+889
+8% +$685K 1.56% 25
2023
Q1 		$8.94M Buy
10,874
+349
+3% +$263K 1.77% 20
2022
Q4 		$7.59M Sell
10,525
-1
-0% -$738 1.64% 21
2022
Q3 		$7.25M Buy
10,526
+439
+4% +$276K 1.68% 23
2022
Q2 		$5.96M Buy
10,087
+354
+4% +$230K 1.34% 28
2022
Q1 		$6.79M Buy
9,733
+515
+6% +$326K 1.29% 28
2021
Q4 		$5.83M Buy
9,218
+1,362
+17% +$837K 1.02% 28
2021
Q3 		$4.75M Buy
7,856
+1,493
+23% +$927K 0.91% 30
2021
Q2 		$3.56M Buy
6,363
+2,826
+80% +$1.43M 0.7% 34
2021
Q1 		$1.67M Buy
+3,537
New +$1.72M 0.36% 40

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Dillon & Associates's REGN Position: Q1 2026 in Review

Dillon & Associates increased its Regeneron Pharmaceuticals (REGN) stake by 0.41% in Q1 2026, buying an estimated $13.8K and bringing the position to 4,391 shares worth $3.39M. The position accounts for 0.47% of the portfolio, ranked #39.

Dillon & Associates first reported a position in REGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $14.2M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Dillon & Associates held 4,391 shares of Regeneron Pharmaceuticals worth $3.39M as of Q1 2026.
  • Dillon & Associates bought 18 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $13.8K.
  • Regeneron Pharmaceuticals made up 0.47% of Dillon & Associates's portfolio in Q1 2026, its #39 holding.
  • Dillon & Associates first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Dillon & Associates's Regeneron Pharmaceuticals position peaked at $14.2M in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Dillon & Associates's 13F filing for Q1 2026, filed 7 May 2026.